Citral [5392-40-5]
Katalog-Nummer T3154-100mg
Size : 100mg
Marke : TargetMol
Select Batch
Appearance:Liquid
Color:Transparent
COA HNMR
Product Introduction
Citral AI Summary
Citral exhibits cytotoxicity against human HeLa cells with an IC50 value of 39.65 μg/mL, suggesting its potential to inhibit cancer cell growth effectively. It achieves up to 60% growth inhibition at concentrations of 10 to 30 μg/mL over a 3-day period, indicating promising anti-cancer properties. Additionally, Citral demonstrates significant anti-inflammatory effects by inhibiting ear and paw edema in mouse models and shows analgesic properties by reducing thermal allodynia. However, higher doses of Citral have been associated with toxicity, evidenced by altered latency times and changes in food and water consumption in Swiss mice. This compound presents a compelling candidate for further research in cancer and inflammatory treatments, although its toxicity at elevated doses warrants careful consideration..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Citral A monoterpene, obtained from the essential oil of lemongrass, which has anti-pain and anti-inflammatory properties. |
| Synonyms | alpha-Citral |
| Molecular Weight | 152.23 |
| Formula | C10H16O |
| Cas No. | 5392-40-5 |
| Smiles | C(CCC=C(C)C)(=CC=O)C |
| Relative Density. | 0.89. Temperature:20 °C. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (328.45 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (13.14 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||



